OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2000 Individual Investigator Grant Recipient – William Irvin

William Irvin, M.D.
University of Virginia Medical Center
Vaccine Trial for Ovarian Cancer

Project Summary

Ovarian cancer is an abnormal process within the female human body. Through a process known as “tolerance,” the host immune system does not recognize malignant ovarian cancer cells as abnormal. The cells are tolerated by the immune system and the cancer continues to grow and metastasize in an unabated fashion. The ovarian cancer vaccine trial conducted by Dr. Irvin and his colleagues is designed to activate a woman’s immune system to the malignancy, so the immune system will seek out and destroy the malignant cells. The vaccine will be used in combination with surgery and chemotherapy.

This project was made possible by a generous grant from Johnson & Johnson.